darifenacin

Known as: darifenacin [Chemical/Ingredient], darifenacine, Darifenacina 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2018
0102019962018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
INTRODUCTION AND OBJECTIVE Patient perception of overactive bladder (OAB) treatment outcomes can be a useful indicator of benefit… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2007
2007
BACKGROUND Overactive bladder (OAB) increases in prevalence with advancing age. This study specifically investigated patients >or… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive… (More)
Is this relevant?
2006
2006
A novel muscarinic receptor antagonist, darifenacin, inhibited specific binding of [N-methyl-(3)H]scopolamine ([(3)H]NMS) in the… (More)
Is this relevant?
2006
2006
This double-blind, randomised placebo-controlled, multicentre study evaluated the efficacy, tolerability and safety of 12 weeks… (More)
Is this relevant?
2005
2005
OBJECTIVES To evaluate the efficacy, tolerability and safety of a flexible-dosing strategy with darifenacin, an M(3)-selective… (More)
Is this relevant?
2005
2005
PURPOSE Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced… (More)
Is this relevant?
2005
2005
A randomized, double-blind, placebo-controlled, four-way crossover, safety study of darifenacin versus oxybutynin was carried out… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2005
2005
OBJECTIVE To evaluate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA… (More)
Is this relevant?
2005
2005
OBJECTIVE To evaluate the pharmacodynamic effects of darifenacin (a muscarinic M(3) selective receptor antagonist) and… (More)
Is this relevant?